Tropical Journal of Pharmaceutical Research
Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, Nigeria
Vol. 16, No. 2, 2017, pp. 445-451
Bioline Code: pr17058
Full paper language: English
Document type: Research Article
Document available free of charge
Tropical Journal of Pharmaceutical Research, Vol. 16, No. 2, 2017, pp. 445-451
© Copyright 2017 - Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 300001 Nigeria.
In-silico investigations into natural products as non-nucleoside DNA methyltransferase 1 inhibitors for treating epi-mutation in gastric cancer|
Li, Dong-fang; Wang, Rui-xiao; Yan, Yong-xia; Jin, Guo-liang; Song, Guo-hui; Ma, Deng-bin & Guan, Li
Purpose: To explore in silico methods to search for the best reported non-nucleoside DNA
methyltransferase 1 (DNMT1) inhibitor of epimutation in gastric cancer.
Methods: A dataset of reported non-nucleoside DNMT1 inhibitors was used to target the active site of
crystallized DNMT1 protein. Molecular docking simulations were carried out using AutoDock 4.2.6 l. The
results were analyzed using Discovery studio visualizer.
Results: In silico analysis of known natural non-nucleoside DNMT1 inhibitors gave genistein as the top
ranked compound with ΔG of -6.39 Kcal/mol. Further, the results indicated that epigallocatechin gallate
and curcumin are poor non-nucleoside DNMT1 inhibitors, as the in silico data suggest that they failed to
bind to the catalytic site of DNMT1.
Conclusion: The results indicate that genistein is the top rated compound for DNMT1 inhibition.
Previous in vitro and in vivo work by other researchers seem to validate the findings of the study.
Epi-mutation; DNA methyltransferase; Non-nucleoside; DNMT1 inhibitor; Docking
Alternative site location: http://www.tjpr.org